Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer

• Published in: Journal of comparative effectiveness research Vol. 10; no. 13; pp. 1021 - 1030
• Main Authors: McCrea, Charles, Hettle, Robert, Gulati, Poonam, Taneja, Ankush, Rajora, Preety
• Format: Journal Article
• Language: English
• Published: Future Medicine Ltd 01-09-2021
• Subjects: BRCA; breast cancer; breast cancer gene; HER2; HER2-negative; metastatic breast cancer; Olaparib
• ISSN: 2042-6305; 2042-6313
• DOI: 10.2217/cer-2021-0097

Two poly(ADP-ribose) polymerase (PARP) inhibitors olaparib and talazoparib are approved for patients with germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer.
A Bayesian fixed-effects indirect treatment comparison (ITC) analysis was performed to simulate the comparative efficacy (primary outcome of progression-free survival [PFS]) and safety of PARP inhibitor monotherapy.
ITC of data from the OlympiAD (olaparib) and EMBRACA (talazoparib) studies suggested no significant difference in efficacy (PFS) between olaparib and talazoparib. However, there were differences in specific adverse events; patients receiving olaparib had a higher rate of nausea and vomiting, while those receiving talazoparib had a higher rate of alopecia and anemia.
These data support the benefit of the PARP inhibitor class in gBRCAm HER2-negative metastatic breast cancer.